Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LYBREL vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of levonorgestrel and ethinyl estradiol: suppression of gonadotropins (FSH and LH) via negative feedback, inhibiting ovulation; thickening of cervical mucus to impede sperm penetration; alteration of endometrium to reduce implantation likelihood.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Prevention of pregnancy
Prevention of pregnancy
One tablet (levonorgestrel 0.1 mg/ethinyl estradiol 0.02 mg) orally once daily for 21 days, followed by 7 placebo tablets for 28-day cycle.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Terminal elimination half-life: 27 ± 8 hours; requires ~5 days to reach steady-state; clinical significance: missed doses lead to rapid loss of contraceptive efficacy.
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Levonorgestrel: primarily metabolized via reduction, hydroxylation, and conjugation; CYP3A4 involvement. Ethinyl estradiol: metabolized by CYP3A4 and undergoes glucuronidation and sulfation.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Renal: 50-60% as metabolites, ~20% as parent drug; fecal: 30-40%; biliary: 10-20%.
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
99% bound to albumin and sex hormone-binding globulin (SHBG).
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Vd: 1.7 ± 0.3 L/kg; indicates extensive tissue distribution (e.g., reproductive organs, liver).
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral: 88% (range 80-95%); first-pass metabolism reduces systemic exposure by ~12%.
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (GFR <30 m L/min); use not recommended.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Contraindicated in Child-Pugh class B and C hepatic impairment. Use with caution in Child-Pugh class A; monitor liver function.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Safety and efficacy not established in postmenarchal pediatric patients for oral contraception. Use same dosing as adults for appropriate indications.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
Not indicated for use in postmenopausal women; no age-specific data.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women >35 years) and with number of cigarettes smoked. Women who use oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Thrombotic disorders and cardiovascular events (especially in smokers >35 years),Elevated blood pressure,Gallbladder disease,Hepatic neoplasia,Glucose intolerance,Hereditary angioedema,Chloasma,Ocular changes (e.g., retinal thrombosis) requiring discontinuation
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
Renal or hepatic impairment,Known or suspected pregnancy,Undiagnosed abnormal uterine bleeding,History of or current thromboembolic disorders (e.g., DVT, PE),Cerebrovascular or coronary artery disease,Known or suspected breast carcinoma,Estrogen-dependent neoplasia,Active liver disease (e.g., acute viral hepatitis),Hypersensitivity to any component
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
No specific foods are known to interact with Lybrel. Grapefruit juice may slightly increase ethinyl estradiol levels but effect is not clinically significant. Avoid St. John's wort as it may reduce contraceptive efficacy.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
Combined hormonal contraceptives (CHCs) like Lybrel (levonorgestrel/ethinyl estradiol) are contraindicated in pregnancy due to potential fetal harm. First trimester exposure is associated with a slightly increased risk of congenital anomalies, particularly cardiovascular and limb defects, though absolute risk is low. Second and third trimester exposure may lead to adverse outcomes including fetal growth restriction, preterm birth, and neonatal withdrawal symptoms. Data from observational studies suggest no major teratogenic risk at typical contraceptive doses, but use is not recommended once pregnancy is confirmed.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Small amounts of ethinyl estradiol and levonorgestrel are excreted in breast milk. The M/P ratio for ethinyl estradiol is approximately 0.05-0.1; for levonorgestrel, it is about 0.1-0.3. Combined hormonal contraceptives may reduce milk production and composition, especially in early postpartum period. Lybrel is not recommended during breastfeeding until weaning, or for at least 6 months postpartum if breastfeeding is established. Progestin-only contraceptives are preferred.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
Lybrel is contraindicated in pregnancy; no dose adjustment is indicated as it should be discontinued immediately upon pregnancy diagnosis. Pharmacokinetic changes in pregnancy (e.g., increased clearance of ethinyl estradiol and levonorgestrel) are not relevant as the drug is not used therapeutically during pregnancy.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
Lybrel is a continuous combined oral contraceptive (COC) containing levonorgestrel 90 mcg and ethinyl estradiol 20 mcg, designed to eliminate monthly withdrawal bleeding. It is taken daily without placebo pills. Breakthrough bleeding and spotting are common in the first 6–12 months. Patients should be counseled that amenorrhea may take up to a year to achieve. Lybrel does not protect against STIs. It is contraindicated in smokers over 35, hypertension (≥160/100 mm Hg), migraine with aura, and thromboembolic disorders. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John's wort) may reduce efficacy.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take one pill every day at the same time, with or without food. There are no placebo pills, so you will take an active pill daily.,You may experience irregular bleeding or spotting, especially during the first 6–12 months. This is normal and usually decreases over time.,Do not expect a regular menstrual period. Most women will have no bleeding after one year of use.,If you miss pills, follow the package instructions. Missing pills increases the risk of pregnancy and may cause bleeding.,Use a backup method of contraception (like condoms) if you miss two or more pills or start a new pack late.,This medication does not protect against HIV or other sexually transmitted infections.,Tell your healthcare provider if you have new or severe headaches, chest pain, leg pain, vision changes, or jaundice.,Do not smoke while taking this medication, as smoking increases the risk of serious cardiovascular side effects.,Inform all healthcare providers that you are taking Lybrel, especially before surgery or blood tests.,Store at room temperature away from moisture and heat.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LYBREL vs ALYACEN 7/7/7, answered by our medical review team.
LYBREL is a Oral Contraceptive that works by Combination of levonorgestrel and ethinyl estradiol: suppression of gonadotropins (FSH and LH) via negative feedback, inhibiting ovulation; thickening of cervical mucus to impede sperm penetration; alteration of endometrium to reduce implantation likelihood.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LYBREL and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LYBREL is: One tablet (levonorgestrel 0.1 mg/ethinyl estradiol 0.02 mg) orally once daily for 21 days, followed by 7 placebo tablets for 28-day cycle.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LYBREL and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LYBREL is classified as Category C. Combined hormonal contraceptives (CHCs) like Lybrel (levonorgestrel/ethinyl estradiol) are contraindicated in pregnancy due to potential fetal harm. First trimester exposure is ass. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.